Want to see AU:ILA full AI Analyst Report?
Top Page
Island Pharmaceuticals Ltd
(Sydney:ILA)
Select Model
Select Model
Rating:51Neutral
Price Target:
AU$0.39
â–¼(-2.00% Downside)
Action:Reiterated
Date:07/09/26
The overall score of 51 reflects a mixed outlook. The company's solid balance sheet and recent equity raise provide financial stability and runway for its research, which is a key strength. However, the lack of revenue, persistent losses, and negative cash flow weigh on the score. Technically, the stock shows bullish momentum but appears overbought, suggesting caution. Valuation remains challenging due to the absence of earnings. As a development-stage biotech, success hinges on clinical progress and future commercialization.
Positive Factors
Low financial leverage
Zero reported debt and materially higher equity provide durable solvency and financial flexibility. For an R&D-intensive biotech, low leverage reduces near-term refinancing pressure, preserving capacity to fund trials and operations across the next several quarters without immediate debt servicing constraints.
Negative Factors
Sharp revenue decline
A roughly 70% YoY revenue drop sharply reduces internal funding capacity and signals weak commercial or milestone timing. Such volatility undermines cash-flow predictability, making multi-quarter planning harder and increasing likelihood of external financing needs that can dilute shareholders or change strategic plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Low financial leverage
Zero reported debt and materially higher equity provide durable solvency and financial flexibility. For an R&D-intensive biotech, low leverage reduces near-term refinancing pressure, preserving capacity to fund trials and operations across the next several quarters without immediate debt servicing constraints.
Read all positive factors
Island Pharmaceuticals Ltd (ILA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$145.09M
Dividend YieldN/A
Average Volume (3M)781.24K
Price to Earnings (P/E)―
Beta (1Y)-0.68
Revenue GrowthN/A
EPS Growth-9.57%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.03
Shares Outstanding296,096,680
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.09
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Island Pharmaceuticals Ltd Business Overview & Revenue Model
Company Description
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101...
How the Company Makes Money
null...
Island Pharmaceuticals Ltd Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
78
Positive
Cash Flow
42
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 22.07K | 118.91K | 1.25M | 11.06K | 0.00 | 0.00 |
| Gross Profit | -729.59K | -1.29M | -1.01M | 11.06K | 0.00 | 0.00 |
| EBITDA | -7.37M | -4.07M | -2.82M | -2.82M | -2.61M | -2.13M |
| Net Income | -7.20M | -3.92M | -2.86M | -2.83M | -2.61M | -2.13M |
Balance Sheet | ||||||
| Total Assets | 8.02M | 7.49M | 2.56M | 2.05M | 4.90M | 6.64M |
| Cash, Cash Equivalents and Short-Term Investments | 6.87M | 7.25M | 1.66M | 2.00M | 4.79M | 6.46M |
| Total Debt | 0.00 | 0.00 | 421.97K | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 860.15K | 336.43K | 1.05M | 263.85K | 580.73K | 236.83K |
| Stockholders Equity | 7.16M | 7.16M | 1.52M | 1.79M | 4.32M | 6.40M |
Cash Flow | ||||||
| Free Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Operating Cash Flow | -3.67M | -2.77M | -3.16M | -2.71M | -1.88M | -938.24K |
| Investing Cash Flow | -841.70K | 0.00 | 0.00 | 0.00 | 0.00 | 77.37K |
| Financing Cash Flow | 7.41M | 8.36M | 2.79M | -171.36K | 0.00 | 7.30M |
Island Pharmaceuticals Ltd Technical Analysis
Positive
0.40
Price Trends
0.42
Positive
0.39
Positive
0.41
Positive
Market Momentum
0.01
Negative
65.48
Neutral
57.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ILA, the sentiment is Positive. The current price of 0.4 is below the 20-day moving average (MA) of 0.44, below the 50-day MA of 0.42, and below the 200-day MA of 0.41, indicating a bullish trend. The MACD of 0.01 indicates Negative momentum. The RSI at 65.48 is Neutral, neither overbought nor oversold. The STOCH value of 57.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ILA.
Island Pharmaceuticals Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$186.12M | -11.40 | -278.87% | ― | 1219.92% | 38.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$145.09M | -15.96 | -100.58% | ― | ― | -9.57% | |
45 Neutral | AU$78.11M | -0.92 | -69.20% | ― | ― | -73.11% | |
44 Neutral | AU$171.51M | -7.93 | -134.14% | ― | ― | -70.59% | |
43 Neutral | AU$104.86M | -1.96 | -265.55% | ― | -26.58% | -100.90% | |
38 Underperform | AU$111.61M | -3.22 | 279.21% | ― | ― | -37.23% |
* Healthcare Sector Average
AU:ILA
Island Pharmaceuticals Ltd
0.49
0.28
133.33%
AU:ACW
Actinogen Medical
0.05
0.02
64.29%
AU:PAR
Paradigm Biopharmaceuticals
0.18
-0.12
-40.68%
AU:IMM
Immutep Ltd
0.05
-0.20
-78.80%
AU:DXB
Dimerix Limited
0.31
-0.15
-32.61%
AU:RCE
Recce Pharmaceuticals Ltd.
0.37
-0.07
-15.12%
Island Pharmaceuticals Ltd Corporate Events
Island Pharmaceuticals advances Galidesivir program and secures key biodefence approvals
Jul 30, 2026
Island Pharmaceuticals reported strong progress in the June quarter across its flagship Galidesivir program, advancing regulatory, manufacturing and clinical foundations for development under the U.S. FDA’s Animal Rule pathway. The company b...
Island Pharmaceuticals to showcase antiviral pipeline progress at TechKnow Invest Roadshow
Jul 26, 2026
Island Pharmaceuticals has announced that its non-executive chairman Jason Carroll will present at the TechKnow Invest Roadshow in Melbourne and Sydney, providing investors with an update on regulatory and clinical progress. The company will outli...
Island Pharmaceuticals Issues 4 Million Unquoted Options Under New Appendix 3G
Jul 13, 2026
Island Pharmaceuticals has notified the market of the issue of 4,000,000 unquoted options under the ASX Appendix 3G framework. The options, which carry various exercise prices and expiry dates, were issued on 16 April 2026 and represent a new clas...
Island Pharmaceuticals Issues Unquoted Options Under Employee Incentive Scheme
Jul 13, 2026
Island Pharmaceuticals Ltd is an Australian-listed biotechnology company focused on developing pharmaceutical products. The company is traded on the ASX under the ticker ILA and operates within the biopharmaceutical sector, pursuing drug developme...
Island Pharmaceuticals Issues 500,000 Unquoted Options Under Employee Incentive Plan
Jul 13, 2026
Island Pharmaceuticals has issued 500,000 unquoted options under its employee incentive scheme, with these securities expiring on various dates and at various exercise prices, and subject to transfer restrictions until those conditions lapse. The ...
Island Pharmaceuticals Issues 500,000 Unquoted Options Under Employee Incentive Plan
Jul 13, 2026
Island Pharmaceuticals has issued 500,000 unquoted options under its employee incentive scheme, with the options expiring on various dates and carrying various exercise prices. The new securities, recorded under ASX code ILAAL, are subject to tran...
Island Pharmaceuticals Builds Antiviral Portfolio Around Galidesivir
Jul 8, 2026
Island Pharmaceuticals Ltd, listed on the ASX under ticker ILA, operates in the biopharmaceutical sector with a core focus on antiviral treatments for serious viral diseases. Its lead effort is the development of Galidesivir as a multi-filovirus c...
Island Pharmaceuticals Options Lapse, Simplifying Capital Structure
Jul 7, 2026
Island Pharmaceuticals has reported the cessation of 230,000 listed options with an exercise price of $0.21 that expired on 28 April 2026 without being exercised or converted. The expiry modestly streamlines the company’s capital base by rem...
Island Pharmaceuticals Wins Approval to Deploy Galidesivir in Bundibugyo Ebola Outbreak
Jul 6, 2026
Island Pharmaceuticals has secured all necessary government and regulatory approvals in Uganda to use its antiviral candidate Galidesivir on a compassionate basis during the escalating Bundibugyo Ebola epidemic. The program, sponsored by the Ugand...
Island Pharmaceuticals Requests ASX Trading Halt Ahead of Ebola Trial Update
Jul 3, 2026
Island Pharmaceuticals Ltd has requested a trading halt on its ordinary shares on the ASX, effective from 3 July 2026, pending a market announcement. The halt is expected to last until either the commencement of normal trading on 7 July 2026 or th...
Island Pharmaceuticals gains key Singapore patent for ISLA-101 antiviral
Jul 2, 2026
Island Pharmaceuticals has secured a Singapore patent covering the use of its lead antiviral candidate ISLA-101 as a standalone therapy for flavivirus infections, including Dengue, and for Chikungunya virus. The patent, owned by Monash University ...
Island Pharmaceuticals Wins FDA Orphan Status for Marburg Antiviral Galidesivir
Jun 16, 2026
Island Pharmaceuticals has secured a significant regulatory boost with the U.S. Food and Drug Administration granting Orphan Drug Designation to its antiviral candidate Galidesivir for post-exposure prophylaxis of Marburg virus disease. The status...
Island Pharmaceuticals Showcases New PROTECT Study Data at Asia Dengue Summit
Jun 16, 2026
Island Pharmaceuticals Ltd, an Australian antiviral drug developer listed on the ASX, is concentrating on therapies for urgent viral diseases and biosecurity threats through its ISLA-101 and Galidesivir programs. ISLA-101 is being repurposed for d...
Island Pharmaceuticals expands US army research pact to advance Marburg antiviral
Jun 9, 2026
Island Pharmaceuticals has expanded its Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases and The Geneva Foundation, securing access to USAMRIID’s Biosafety Level 4 facilities...
Island Pharmaceuticals advances Galidesivir with new GMP manufacturing deal
Jun 3, 2026
Island Pharmaceuticals has engaged global contract research, development and manufacturing group PI Health Sciences to undertake a GMP manufacturing campaign for its lead antiviral Galidesivir. The program includes analytical method validation, re...
Island Pharma hires ex-BioCryst leader to accelerate Galidesivir biodefence push
May 21, 2026
Island Pharmaceuticals has appointed former BioCryst Pharmaceuticals executive Raymond Taylor as Senior Scientific Fellow to advance its lead antiviral, Galidesivir, particularly for Marburg Virus Disease under the U.S. FDA’s Animal Rule pat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.